MedTrace Logo

Efficacy Study of Nifedipine Controlled-Release Tablets (Xin Ran) to Treat Mild to Moderate Essential Hypertension

NCT02031861 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 38

Last updated 2015-02-05

No results posted yet for this study

Summary

The purpose of this study is to compare nifedipine controlled-release (CR) tablets (Xin Ran) with nifedipine controlled-release tablets (Adalat）in the treatment of mild to moderate essential hypertension.

Conditions

  • Essential Hypertension

Interventions

DRUG

nifedipine CR tablets (Xin Ran)

DRUG

nifedipine CR tablets (Adalat)

Sponsors & Collaborators

  • Shanghai Shyndec Pharmaceutical Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Pingjin Gao · Ruijin Hospital Affiliated to Shanghai Jiao Tong University Medical School

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-02-28
Primary Completion
2014-07-31
Completion
2014-07-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02031861 on ClinicalTrials.gov